Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Université Paris Cité · Düsseldorf University Hospital · +3 more institutions
Abstract
PURPOSE: In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2- and high-risk myelodysplastic syndromes. Approximately one third of these patients were classified as having acute myeloid leukemia (AML) under current WHO criteria. This analysis compared the effects of azacitidine versus CCR on OS in this subgroup. PATIENTS AND METHODS: Patients were randomly assigned to receive subcutaneous azacitidine 75 mg/m(2)/d or CCR (best supportive care [BSC] only, low-dose cytarabine (LDAC), or intensive chemotherapy [IC]). RESULTS: Of the 113 elderly patients (median age, 70 years) randomly assigned to…
Citation impact
- FWCI
- 29.67
- Percentile
- 100%
- References
- 52
Authors
16- PFPierre FenauxCorresponding
Université Paris Cité, Düsseldorf University Hospital, Université Sorbonne Paris Nord, Assistance Publique – Hôpitaux de Paris, Heinrich Heine University Düsseldorf
- GJGhulam J. Mufti
Université Paris Cité, Düsseldorf University Hospital, Université Sorbonne Paris Nord, Assistance Publique – Hôpitaux de Paris, Heinrich Heine University Düsseldorf
- EHEva Hellström‐Lindberg
Université Paris Cité, Düsseldorf University Hospital, Université Sorbonne Paris Nord, Assistance Publique – Hôpitaux de Paris, Heinrich Heine University Düsseldorf
- VSValeria Santini
Université Paris Cité, Düsseldorf University Hospital, Université Sorbonne Paris Nord, Assistance Publique – Hôpitaux de Paris, Heinrich Heine University Düsseldorf
- NGNorbert Gattermann
Université Paris Cité, Düsseldorf University Hospital, Université Sorbonne Paris Nord, Assistance Publique – Hôpitaux de Paris, Heinrich Heine University Düsseldorf
Topics & keywords
- Azacitidine
- Medicine
- Myeloid leukemia
- Internal medicine
- Cytarabine
- Hazard ratio
- Myelodysplastic syndromes
- Leukemia
- Good health and well-being